Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors by Zhaleiko, I.O. et al.
112 Experimental Oncology 36, 112–116, 2014 (June)
DETERMINATION OF THE OPTIMAL CHEMOTHERAPY DRUGS 
PRETREATMENT TIME THROUGH CULTIVATION OF HEMOPOIETIC 
CELLS IN CML-PATIENTS TREATED WITH TYROSINE KINASE 
INHIBITORS
I.O. Zhaleiko1,*, T.P. Perekhrestenko2, D.I. Bilko1, I.S. Dyagil3, N.M. Bilko1
1Centre of Molecular and Cell Research of the National University “Kyiv-Mohyla Academy”, Kyiv 04655, 
Ukraine
2SI “Institute of Hematology and Transfusiology” of the NAMS of Ukraine, Kyiv 04060, Ukraine
3National Research Center for Radiation Medicine of the NAMS of Ukraine, Kyiv 04050, Ukraine
Background: Targeted therapy drugs, including imatinib, are used for inhibiting the marker oncoprotein of chronic myeloid leuke-
mia — BCR-ABL tyrosine kinase. However, in some patients the drug resistance can emerge too rapidly and a previous treatment 
with chemotherapy drugs can lead to formation of resistance. Aim: To evaluate the influence of drugs that were used prior to the ima-
tinib on the performance of the functional activity of bone marrow cells from chronic myeloid leukemia patients and their indivi dual 
responses to therapy. Methods: Bone marrow aspirate from 57 patients, who were getting busulfan (19 patients) or hydroxy-
carbamide (38 patients) prior to imatinib was studied with cytogenetic and tissue culture methods in vitro. Results: Obtained data 
suggested that pretreatment with busulfan, regardless of duration, negatively affects the response to further therapy with imatinib. 
Instead, after using hydroxycarbamide as a previous therapy for six month, there was optimal response to imatinib. In those cases 
when duration of pretreatment with hydroxycarbamide was increased to a year or more, there was a suboptimal response and a re-
sistance to imatinib therapy. In addition, there was a positive correlation between the number of cell aggregates (colonies and 
clusters) in semisolid agar and the duration of a prior treatment with hydroxycarbamide, if previous therapy did not exceed 20 months. 
With an increase of pretreatment terms to 21 months or more, such a correlation was not observed. Conclusions: These results 
suggest that chemotherapeutic agents (busulfan and hydroxycarbamide) may additionally contribute to the accumulation of muta-
tions in the genome of leukemic cell clone affecting the behavior of these cells in vitro.
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In recent years, tyrosine kinase inhibitors (TKI) 
such as imatinib, are used as effective therapeutic 
agents in chronic myeloid leukemia (CML). The ac-
tion mechanism of this drug is based on the inhibition 
of the BCR-ABL tyrosine kinase, which is a product 
of the oncogene with a same name, formed as a result 
of reciprocal translocation between chromosomes 
9 and 22 [1, 2]. Chromosome 22 with a shortened long 
arm is called Philadelphia chromosome, or Ph chromo-
some. This is a cytogenetic marker of CML [3].
However, the experience of imatinib monotherapy 
usage showed that about 25% of patients develop re-
sistance after 12 months [4]. Most researchers believe 
that the most common causes of such resistance are 
point mutations in the gene BCR-ABL [2–4]. Moreover, 
the cause of resistance to therapy can also be attri-
buted to amplification or increase of gene BCR-ABL 
expression, an additional chromosomal aberrations 
and expression of multiple drugs resistance pro-
teins [3–5].
Center of Supervision for Cancer Patients Ontario 
developed a treatment program for patients with CML 
using TKI, which indicates that imatinib should be used 
as first-line therapy, or it can be used in those cases 
where patients have resistance to chemotherapeutic 
drugs (hydroxycarbamide, interferon, etc.) [6]. Fur-
thermore, in everyday medical practice in Ukraine 
a large numbers of patients with CML were treated 
with chemotherapeutic agents, such as busulfan and 
hydroxycarbamide before the TKI therapy. The chemi-
cal nature of busulfan is derived from of disulfuronic 
acid with alkyl action that has a high tropism for DNA 
of myeloid progenitors of hematopoiesis [7]. The use 
of busulfan can reduce the size of leukemic clone, 
but it continues to dominate in hematopoiesis 
of the patient, and even during complete hemato-
logic remission in all cells of bone marrow of patients 
the presence of the Philadelphia chromosome could 
be indicated [8]. Hydroxycarbamide is an inhibitor 
of ribonuclease. It is an enzyme that is essential for 
DNA synthesis. The drug can improve the survival rate 
of patients with CML by lengthening the chronic phase 
of the disease [9]. However, given the fact that the 
cells of leukemic clone are characterized by genomic 
instability, the use of chemotherapy drugs serves 
as an additional factor contributing to the selective 
accumulation of mutations, their application prior 
to imatinib therapy may accelerate the process of re-
sistance development of leukemic cell clone [10, 11]. 
However, the question of influence of treatment dura-
tion with prior chemotherapeutic drugs on the forma-
tion of the resistance of bone marrow cells in CML 
to imatinib therapy still remains unresolved.
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The aim of this work was to evaluate the influence 
of drugs that were used prior to the imatinib on the per-
formance of the functional activity of bone marrow 
cells from CML patients and their individual responses 
to therapy based on the evaluation of in vitro functional 
activity of the hematopoietic cells.
MATHERIALS AND METHODS
228 bone marrow cultures from 57 patients who were 
taking busulfan and hydroxycarbamide in standard doses 
and standard scheme before treatment with imatinib 
(400 mg/day) were analyzed. All patients before the study 
signed a voluntary informed consent. All patient samples 
were obtained under Research Ethics Board. Wide varia-
tion in the duration of the aforementioned chemothera-
peutic drugs prior to imatinib therapy made the direct 
assessment of this factor impact on the performance 
of the functional activity of bone marrow patients more 
complicated. Therefore, patients were divided into three 
groups, depending on the response to imatinib therapy: 
those with optimal response to imatinib (the bone mar-
row of patients had no cells containing the Philadelphia 
chromosome after 12 months of therapy), patients with 
suboptimal response (the bone marrow showed 35% 
of cells containing the Philadelphia chromosome after 
12-month treatment), patients with resistance (after 
12 months of treatment the bone marrow had more than 
35% of cells containing the Philadelphia chromosome).
In order to observe the patient’s response to ima-
tinib therapy, we performed a cytogenetic analysis 
of bone marrow cells of patients with the direct method 
and using cell culture CFU-GM assay with even and 
 G-differential staining, detecting the percentage 
of cells containing the Philadelphia chromosome.
Determination of the functional activity of bone 
marrow cells was done by culturing in vitro in semi-
solid agar with the addition of 20% fetal bone serum 
(Sigma, USA), 0.33% bacterial agar (“Difco”, USA), 
50 ng/ml GM-CSF (Sigma, USA), and antibiotics 
(50 IU/ml penicillin, 50 mg/ml streptomycin). Cultiva-
tion lasted for 14 days under conditions of absolute 
humidity and 5% CO2. After the end of the cultivation 
the numbers of colonies and clusters were counted 
under an inverted microscope (Nikon, Japan).
For cluster (cluster-forming unit — ClFU) 
we took a cell aggregate, which included more than 
40 cells (Fig. 1). A typical colony (colony-forming 
unit-granulocyte/macrophage — CFU-GM) included 
40 to several hundred cells. Proliferative potential (PP) 
was calculated as a ratio between granulocyte-mac-
rophage colonies and clusters.
Statistical analysis of the results was carried out 
using Mann — Whitney nonparametric comparison. 
Conclusion of the statistical significance of the results 
made at p < 0.05. For estimation of interrelations 
between obtained indexes, the correlational analysis 
with determination of Spearman’s rank correlation 
coefficient has been conducted.
RESULTS AND DISCUSSION
The fact that previous therapy with cytotoxic drugs 
has a negative impact on overall survival of patients 
with CML [12], gives us an idea to investigate he-
matopoietic stem cells and their precursors in cell 
culture in vitro as a criterion for assessing the impact 
of chemotherapeutic agents on subsequent functional 
activity of bone marrow cells with CML and response 
to the rapy TKI. For example, in previous studies it has 
been shown that the characteristics of the functional ac-
tivity of hematopoietic cells in CML have predictive value 
for the likelihood of obtaining remission or progression 
of the disease [13, 14]. We used this phenomenon to study 
the impact of busulfan and hydroxycarbamide on leukemic 
clone cell sensitivity to further imatinib therapy.
a
b
Fig. 1. Types of bone marrow cell aggregates on day 14 of culti-
vation in semisolid agar in vitro: a — colony, b — cluster
Based on the experimental data it was shown that 
patients, who received busulfan as basic therapy, regard-
less of the number of months of the admission, showed 
no optimal response to further therapy with imatinib that 
resulted in high PP. In addition, there was no statistically 
significant difference between the numbers of colonies 
and clusters in the two groups. Thus, patients with 
suboptimal response to imatinib therapy had proli-
ferative capacity index of 1.92 ± 0.2 and the number 
of colonies and clusters reached 125.0 ± 7.3 and 51.0 ± 
3.2 on 1•105 explanted mononuclear cells respectively. 
In turn, patients, who were characterized by the lack of re-
sponse to imatinib therapy, had a PP index of 3.21 ± 0.1, 
the number of colonies and clusters in the cell culture 
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in vitro was 188.0 ± 5.8 and 27.0 ± 4.5 for 1•105 explanted 
cells respectively (Table 1).
Table 1. Characteristics of the functional activity of bone marrow cells 
of patients with busulfan prior therapy
Response The number of colonies
The number 
of clusters
The num-
ber of Ph+ PP
Optimal response − − − −
Suboptimal response 125.0 ± 7.3 51.0 ± 3.2 45.0 ± 0.4 1.92 ± 0.2
Resistance 188.0 ± 5.8 27.0 ± 4.5 81.0 ± 1.1 3.21 ± 0.1
These results may indicate that administering bu-
sulfan as basic therapy increases the risk of mutations 
in the cells of leukemic clone because of its affinity 
to the cell DNA. This is the reason for the formation 
“cross-linking” in the DNA molecules [15], which leads 
to genomic instability and development of the resis-
tance to subsequent therapy with TKI group, in par-
ticular, to the imatinib.
Minimum term of hydroxycarbamide usage in a stu-
died cohort of patients before imatinib therapy ranged 
from 4 to the maximum of 90 months. But in patients 
with an optimal response to imatinib therapy, the ave-
rage hydroxycarbamide pretreatment term was 
6.5 ± 2.1 months. In turn, patients who had a sub-
optimal response to therapy with hydroxycarbamide 
was 12.0 ± 0.4 months and for patients with acquired 
resistance the pretreatment, this term reached 
22.0 ± 3.6 months; there were also 2 patients, who 
received imatinib therapy with hydroxycarbamide for 
54 and 90 months. Such long pretreatment had a nega-
tive effect on the formation of response to imatinib, 
because these patients are characterized by initial 
resistance to the drug.
When comparing the functional activity of bone 
marrow cells of patients, who were taking imatinib 
therapy before hydroxycarbamide, it was observed 
that increase in the duration of the hydroxycarbamide 
therapy leads to the increased functional activity 
of bone marrow cells of patients. Thus, in the group 
of patients, who were taking hydroxycarbamide for 
6.5 ± 2.1 months, the numbers of colonies in semisolid 
agar in vitro was 16.1 ± 5.5 CFU per 1•105 explanted 
mononuclear cells. In patients with doubled pe-
riod of hydroxycarbamide pretreatment, the numbers 
of colonies was 4.8 times higher than in patients, who 
received hydroxycarbamide for 6.5 ± 2.1 months and 
was 78.0 ± 2.2 CFU per 1•105 explanted cells. With 
increasing duration of hydroxycarbamide pretreatment 
up to 22.0 ± 3.6 months, the number of CFU reached 
82.0 ± 1.2 on 1•105 explanted cells, indicating a dis-
proportional increase in the numbers of cloned cells 
with unlimited PP, which are able to form colonies 
in semisolid agar, depending on the hydroxycarbamide 
pretreatment duration [16].
Numbers of clusters in culture in vitro for diffe-
rent groups of patients changed similarly to changes 
in the numbers of colonies in semisolid medium. 
Thus, in patients with an optimal response to imatinib 
therapy the number of clusters was 56.0 ± 9.0 ClFU 
1•105 explanted cells and in patients with subopti-
mal response to the drug the number of clusters was 
2.3 times higher, reaching 130.0 ± 5.6 ClFU 1•105 ex-
planted mononuclears. In the group of patients with 
acquired resistance, where hydroxycarbamide pre-
treatment term was about 22.0 ± 3.6 months, the ClFU 
number in culture was 1.5 times higher and reached 
198.0 ± 1.3 to 1•105 explanted cells, compared to pa-
tients whose hydroxycarbamide pretreatment term was 
about 12.0 ± 0.4 months (Table 2).
Table 2. Characteristics of the functional activity of bone marrow cells 
of patients with CML with hydroxycarbamide therapy before using imatinib
Response Duration, months
The num-
ber of co-
lonies
The number 
of clusters
The num-
ber of Ph+ PP
Optimal response 6.5 ± 2.1 16.1 ± 5.5 56.0 ± 9.0 0 0.39 ± 0.1
Suboptimal 
 response 12.0 ± 0.4 78.0 ± 2.2 130.0 ± 5.6 18.0 ± 0.8 1.23 ± 0.1
Resistance 22.0 ± 3.6 82.0 ± 1.2 198.0 ± 1.3 72.0 ± 7.1 1.34 ± 0.2
We were interested in the fact what hydroxy-
carbamide pretreatment duration resulted in improved 
survival of the CML patients. The question was focused 
on the identification of the pretreatment duration 
period with hydroxycarbamide that in patients would 
show optimal response to TKI therapy without any kind 
of suboptimal response and no acquisition of resis-
tance to the drug. In previous studies it was found that 
the value of PP in bone marrow cells, when cultured 
in semisolid agar in vitro, has a prognostic value for the 
imatinib treatment [17]. If the value after six months 
of therapy is lower than PP 1 — there is an optimal re-
sponse to imatinib therapy; if the value is higher than 
the PP 1 — there is a suboptimal response to therapy 
with the threat of the drug resistance [17]. Therefore, 
we determined the PP of different patients groups and 
found that patients with an optimal response to imatinib 
therapy the PP value was 0.39 ± 0.1 and in patients with 
suboptimal response to therapy and with resistance 
to imatinib the value of PP was 1.23 ± 0.1 and 1.34 ± 0.2. 
Thus, based on the value of bone marrow cells PP among 
different groups of patients, an optimal period to use 
hydroxycarbamide as a base treatment of CML before 
applying the imatinib was 6.5 ± 2.1 months. In case 
of extension of previous hydroxycarbamide treatment 
the risk of adverse impact on the formation of leukemic 
cell clone response to further imatinib therapy increases.
In bone marrow samples of patients treated with hy-
droxycarbamide there is a correlation (R = 0.85331) be-
tween indicators of colony forming activity and the dura-
tion of pretreatment with hydroxycarbamide in period 
between 1 and 20 months (Fig. 2). Patients, who had 
a hydroxycarbamide pretreatment for 21 months 
or more, did not show such correlation. In addition, 
there was also a correlation (R = 0.8744) between the 
indices of cluster forming activity and the duration of hy-
droxycarbamide pretreatment in bone marrow samples 
of patients ta king the drug in the 1–20 months time 
interval. Patients with hydroxycarbamide pretreatment 
duration more than 20 months did not show such cor-
relation, same as in the case of colony forming activity. 
However, bet ween the value of PP bone marrow cells 
of patients and hydroxycarbamide pretreatment dura-
tion the correlation was found (R = 0.2143).
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Given the fact that in previous studies, we have 
demonstrated a direct relationship between the 
translocation t(9,22)(q4;q11) in leukemic progenitor 
cells of the bone marrow and their functional acti-
vity  [18], we can assume that with increasing duration 
of hydroxycarbamide treatment, the leukemic clone 
cells genome accumulates mutations that can affect 
the sensitivity of BCR-ABL tyrosine kinase to imatinib 
therapy. This can directly affect the functional activity 
of both cells with unlimited PP in semisolid agar, which 
are able to form colonies and more differentiated 
leukemic cells clone with limited PP in semisolid agar, 
which are able to form clusters [16].
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Fig. 2. Correlation analysis colony forming activity of bone mar-
row cells from CML patients and the duration of pretreatment with 
hydroxycarbamide: a — the number of colonies, b — the number 
of clusters, c — PP
However, some authors hold on to the idea that one 
of the significant causes of mutations in the genome 
of leukemic cells is increased activity of BCR-ABL on-
coprotein [19]. It is believed that the BCR-ABL tyrosine 
kinase is able to induce genomic instability through 
the involvement of several mechanisms, one of which 
is oxidative stress. Reactive oxygen species, produced 
as a result of increased activity of the BCR-ABL tyrosine 
kinase mutations can cause mutations even in the BCR-
ABL gene. That is why the duration of BCR-ABL onco-
protein activity exposure on genes in leukemic cell 
clones is important. In fact, with the increasing duration 
after the formation of the translocation t(9,22)(q4;q11) 
and fusion of BCR-ABL tyrosine kinase, the possibility 
of mutations in the BCR-ABL gene and additional chro-
mosomal translocations raises, that can be the reason for 
the insensitivity of a particular cells to imatinib therapy. 
The use of additional stress factors, such as chemothera-
peutic agents (busulfan and hydroxycarbamide) may 
additionally contribute to the accumulation of mutations 
in the genome of leukemic cell clone.
In conclusion, we have found a relationship between 
the increasing duration of chemotherapeutic drugs pre-
treatment and indicators of functional activity of bone 
marrow cells of patients with CML. In particular, the use 
of busulfan as a preliminary treatment agent before 
using TKI is objectionable due to the fact that regard-
less of the number of months of its admission, patients 
showed the lack of optimal response to subsequent 
imatinib therapy and high PP. In addition, it was found 
that prolonged treatment with hydroxycarbamide (over 
6 months) promotes resistance to TKI. In case of ex-
tension of previous treatment with hydroxycarbamide 
the risk of adverse impact on the formation of leuke-
mic cell clone response to further imatinib therapy 
increases. In addition, there was a positive correlation 
between the numbers of clusters and colonies and 
the duration of previous hydroxycarbamide treatment 
between 1 and 20 months. Patients, who were getting 
hydroxycarbamide pretreatment for 21 months or more, 
did not have such correlation.
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